Semaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, has shown promising effects in reducing cardiovascular events in patients with obesity and heart failure (HF) with preserved ejection fraction (HFpEF) irrespective of concomitant diabetes. Here, GLP1R is linked to diabetes mellitus.